GPC3-targeted CAR-T cell therapy (Huaxiayuan)

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameGPC3-targeted CAR-T cell therapy (Huaxiayuan)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derivedCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionGlypican-3 modulatorsT lymphocyte replacements
TargetsGlypican-3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHuaxiayuan (Shanghai) Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHuaxiayuan (Shanghai) Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A